Jefferies raised the firm’s price target on GE HealthCare (GEHC) to $105 from $95 and keeps a Buy rating on the shares after having hosted a call with CFO Jay Saccaro and other executives. The firm, which was “encouraged” by GE HealthCare’s Q3 performance and leading indicators, sees stable to improving fundamentals and “a strong catalyst path” with consensus appearing to model very little contribution from Flyrcado or Vizamyl/Cerianna, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- GE HealthCare price target raised to $88 from $83 at Citi
- GE HealthCare participates in a conference call with Jefferies
- Roth Capital healthcare analyst holds an analyst/industry conference call
- Promising Growth and Innovation Drive Buy Rating for GE Healthcare Technologies
- GE HealthCare, Mayo Clinic announce GEMINI-RT research collaboration